• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1.7埃分辨率下p53肿瘤抑制蛋白四聚化结构域的晶体结构

Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.

作者信息

Jeffrey P D, Gorina S, Pavletich N P

机构信息

Cellular Biochemistry and Biophysics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

出版信息

Science. 1995 Mar 10;267(5203):1498-502. doi: 10.1126/science.7878469.

DOI:10.1126/science.7878469
PMID:7878469
Abstract

The p53 protein is a tetrameric transcription factor that plays a central role in the prevention of neoplastic transformation. Oligomerization appears to be essential for the tumor suppressing activity of p53 because oligomerization-deficient p53 mutants cannot suppress the growth of carcinoma cell lines. The crystal structure of the tetramerization domain of p53 (residues 325 to 356) was determined at 1.7 angstrom resolution and refined to a crystallographic R factor of 19.2 percent. The monomer, which consists of a beta strand and an alpha helix, associates with a second monomer across an antiparallel beta sheet and an antiparallel helix-helix interface to form a dimer. Two of these dimers associate across a second and distinct parallel helix-helix interface to form the tetramer.

摘要

p53蛋白是一种四聚体转录因子,在预防肿瘤转化中起核心作用。寡聚化似乎对p53的肿瘤抑制活性至关重要,因为缺乏寡聚化的p53突变体无法抑制癌细胞系的生长。p53四聚化结构域(第325至356位氨基酸残基)的晶体结构在1.7埃分辨率下测定,并精修至晶体学R因子为19.2%。该单体由一条β链和一条α螺旋组成,通过一个反平行β折叠和一个反平行螺旋-螺旋界面与第二个单体缔合形成二聚体。其中两个二聚体通过第二个不同的平行螺旋-螺旋界面缔合形成四聚体。

相似文献

1
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.1.7埃分辨率下p53肿瘤抑制蛋白四聚化结构域的晶体结构
Science. 1995 Mar 10;267(5203):1498-502. doi: 10.1126/science.7878469.
2
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.通过多维核磁共振解析p53寡聚化结构域的高分辨率结构
Science. 1994 Jul 15;265(5170):386-91. doi: 10.1126/science.8023159.
3
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.p53肿瘤抑制因子-DNA复合物的晶体结构:理解致癌突变
Science. 1994 Jul 15;265(5170):346-55. doi: 10.1126/science.8023157.
4
Crystal structure of a p53 core tetramer bound to DNA.与DNA结合的p53核心四聚体的晶体结构。
Oncogene. 2009 Jan 22;28(3):325-33. doi: 10.1038/onc.2008.400. Epub 2008 Nov 3.
5
Refined solution structure of the oligomerization domain of the tumour suppressor p53.肿瘤抑制因子p53寡聚化结构域的精细溶液结构
Nat Struct Biol. 1995 Apr;2(4):321-33. doi: 10.1038/nsb0495-321.
6
A meanfield approach to the thermodynamics of a protein-solvent system with application to the oligomerization of the tumor suppressor p53.一种用于蛋白质-溶剂系统热力学的平均场方法及其在肿瘤抑制因子p53寡聚化中的应用。
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):9955-60. doi: 10.1073/pnas.160075697.
7
Structure of the human p53 core domain in the absence of DNA.无DNA情况下人p53核心结构域的结构
Acta Crystallogr D Biol Crystallogr. 2007 Mar;63(Pt 3):276-81. doi: 10.1107/S0907444906048499. Epub 2007 Feb 21.
8
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.与p53肿瘤抑制因子反式激活结构域结合的MDM2癌蛋白的结构。
Science. 1996 Nov 8;274(5289):948-53. doi: 10.1126/science.274.5289.948.
9
Backbone dynamics of the oligomerization domain of p53 determined from 15N NMR relaxation measurements.通过15N NMR弛豫测量确定的p53寡聚化结构域的主链动力学。
Protein Sci. 1995 May;4(5):855-62. doi: 10.1002/pro.5560040505.
10
Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution.分辨率为2.7埃的小鼠p53核心DNA结合结构域的晶体结构。
J Biol Chem. 2001 Apr 13;276(15):12120-7. doi: 10.1074/jbc.M011644200. Epub 2001 Jan 4.

引用本文的文献

1
Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation.肿瘤抑制蛋白p53的Δ133p53α和Δ160p53α亚型主要通过共聚集发挥显性负效应。
Elife. 2025 Jul 21;14:RP106469. doi: 10.7554/eLife.106469.
2
Correlation of p53 oligomeric status and its subcellular localization in the presence of the AML-associated NPM mutant.在急性髓系白血病相关的核仁磷酸蛋白(NPM)突变存在的情况下,p53寡聚状态与其亚细胞定位的相关性。
PLoS One. 2025 May 7;20(5):e0322096. doi: 10.1371/journal.pone.0322096. eCollection 2025.
3
Integration of protein stability and AlphaMissense scores improves bioinformatic impact prediction for p53 missense and in-frame amino acid deletion variants.
蛋白质稳定性与AlphaMissense评分的整合改善了对p53错义及框内氨基酸缺失变体的生物信息学影响预测。
Am J Hum Genet. 2025 May 1;112(5):1003-1014. doi: 10.1016/j.ajhg.2025.01.012. Epub 2025 Apr 14.
4
Structural biology in variant interpretation: Perspectives and practices from two studies.变异解读中的结构生物学:两项研究的观点与实践
Am J Hum Genet. 2025 May 1;112(5):984-992. doi: 10.1016/j.ajhg.2025.03.010. Epub 2025 Apr 14.
5
The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.p53突变在对有丝分裂异常的早期和晚期反应中的作用。
Biomolecules. 2025 Feb 8;15(2):244. doi: 10.3390/biom15020244.
6
Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53.避开基因组守护者:当前针对突变型p53的癌症治疗方法
Front Pharmacol. 2025 Jan 29;16:1529483. doi: 10.3389/fphar.2025.1529483. eCollection 2025.
7
Clustering of variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.将变异聚类到功能类别与癌症风险相关,并可识别李-佛美尼综合征的不同表型。
iScience. 2024 Nov 1;27(12):111296. doi: 10.1016/j.isci.2024.111296. eCollection 2024 Dec 20.
8
The Ashkenazi-Centric G334R Variant of is Severely Impaired for Transactivation but Retains Tumor Suppressor Function in a Mouse Model.的 Ashkenazi 中心 G334R 变体在激活方面严重受损,但在小鼠模型中保留肿瘤抑制功能。
Mol Cell Biol. 2024;44(12):607-621. doi: 10.1080/10985549.2024.2421885. Epub 2024 Nov 8.
9
Navigating the complexity of p53-DNA binding: implications for cancer therapy.解析p53与DNA结合的复杂性:对癌症治疗的启示
Biophys Rev. 2024 Jul 11;16(4):479-496. doi: 10.1007/s12551-024-01207-4. eCollection 2024 Aug.
10
Germline variant affecting p53β isoforms predisposes to familial cancer.胚系变异影响 p53β 异构体,易患家族性癌症。
Nat Commun. 2024 Sep 18;15(1):8208. doi: 10.1038/s41467-024-52551-8.